<SEC-DOCUMENT>0001144204-11-050444.txt : 20110830
<SEC-HEADER>0001144204-11-050444.hdr.sgml : 20110830
<ACCEPTANCE-DATETIME>20110830091536
ACCESSION NUMBER:		0001144204-11-050444
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110830
FILED AS OF DATE:		20110830
DATE AS OF CHANGE:		20110830

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		111064333

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v233720_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: vintage-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: #000000" align="left" noshade size="2" width="100%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 6-K</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report of Foreign Private Issuer</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule 13a-16 or 15d-16</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of the Securities Exchange Act of 1934</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the month of August, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number: <font style="DISPLAY: inline; FONT-WEIGHT: bold">000-51310</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">XTL Biopharmaceuticals Ltd. </font></font>

<div>
<hr style="COLOR: #000000" align="center" noshade size="1" width="20%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation of registrant&#8217;s name into English)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">85 Medinat Hayehudim St., Herzliya</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pituach, PO Box 4033,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Herzliya 46140, Israel </font></font>

<div>
<hr style="COLOR: #000000" align="center" noshade size="1" width="20%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address of principal executive offices)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font style="DISPLAY: inline;" face="Wingdings">x</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Form 40-F<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font style="DISPLAY: inline;" face="Wingdings">o</font></font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font style="DISPLAY: inline;" face="Wingdings">o</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;No<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font style="DISPLAY: inline;" face="Wingdings">x</font></font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;N/A</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font id="TAB1" style="MARGIN-LEFT: 432pt"></font><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated August 30, 2011 is hereby incorporated by reference into the registration statements on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23, 2007 , October 30, 2007 and August 15, 2008, respectively, and the registration statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL Biopharmaceuticals (the "Company") Announces</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proteins Research for the Company's Drug Treatment for Multiple Myeloma</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;&#160;&#160; <br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attached hereto is an English translation (from Hebrew) of an announcement from the Company, as submitted on the Tel Aviv Stock Exchange, that XTL Biopharmaceuticals Ltd. intends to conduct proteins research in connection with the Company's drug treatment for multiple myeloma blood cancer.</font><br>
</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><img src="logo.jpg"><br>
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160; <br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">XTL Biopharmaceuticals Ltd</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">("the Company")</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">August 29, 2011</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dear Sirs,</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Re:&#160;&#160;Immediate Report - Proteins Research for the</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Company's Drug Treatment for Multiple Myeloma</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further to the Company's announcement on May 29<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2011, regarding the receipt of an Orphan-drug designation by the US Food and Drug Administration (FDA) for its recombinant human erythropoietin (rHuEPO) treatment of multiple myeloma blood cancer, the Company hereby announces that, following consultation with its regulatory and scientific advisors in relation to the execution of its phase 2 clinical trial with its rHuEPO drug for the treatment of multiple myeloma cancer, the Company has decided on August 29<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2011, to conduct a research, which includes data collection in relation to the presence of the level of specific proteins in the blood of a group of multiple myeloma patients. The collected research data will assist in focusing the phase 2 clinical trial protocol. The aforementioned data collection shall be integrated in the framework of the rHuEPO phase 2 clinical trial that the Company is planning to conduct. The Company's management and advisors estimate that receipt of an approval to commence a phase 2 clinical trial after the finalization of the research data collection and their combination in the framework of the trial's protocol is expected in the second half of 2012.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company's estimations with the expected schedules for the receipt of an approval to commence a phase 2 clinical trial are forward-looking statements. This information is uncertain and is based on the Company's current information at the time of this immediate report. The actual schedule may be substantially different than reflected in this report, as there is no certainty to the time required to receive the regulatory agencies&#8217; approval to commence the abovementioned trial.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Respectfully;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL Biopharmaceuticals Ltd.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">XTL Biopharmaceuticals Ltd.&#160;85 Medinat Hayehudim St., Herzliya Pituach 46766, Israel Tel:&#160;+972-9-955-7080&#160;Fax:&#160;+972-9-951-9727</font></font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></font></div>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor Relations, XTL Biopharmaceuticals Ltd.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +972 9 955 7080, Email: ir@xtlbio.com</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cautionary Statement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of the statements included in this Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-4-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XTL BIOPHARMACEUTICALS LTD.</font></div>
</td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="42%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="42%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="42%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: August 30, 2011</font></div>
</td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="42%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ David Grossman</font></font></div>
</td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="42%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David Grossman</font></div>
</td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="42%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center">-5-</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_X0S!17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!@````
M`0```&`````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q,3HP.#HR
M.2`Q,SHS,#HT-````````Z`!``,````!``$``*`"``0````!````D:`#``0`
M```!````+0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```N+````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+0"1`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]1=D4-<6NL8UPY!<`5R7^,+ZTYO1\+&K
MZ6\,MS'/!R!#MK:PW<UD[F>H[U%F_P"-#ZLBRL=?Q6>^L!F:`.6\57_];_F[
M/Y"YWZEOZ=U)[OJUU<$XN6[U<2P':ZK(`C]$[_NQ7[59Q8H\(RWQB/S0I@R9
M)68?*3\LGHO\7?UPZMU#/MZ;U.W[2WTG75WN`#F;"W>U[FANYCMZ[[[3C'06
MLD_RA_>O+OK?B](^JN&[HG22]V7U`!V;?8[<\4`S71[0QK&W6#_H)O\`%K]5
MQGYO[8RV3BX;HH:1H^X?G?U:/I?\:CDQ0E$Y1Z(_HQKYE0G($8SZI=3>SZF<
MG':2UUK`1H07"4WVK&_TS/\`.']Z\JZ_]1/K/F]<S\O'PP^B_(LLK?ZE8EKG
M2UVUS]RYWK'U=ZMT0U#J=`H]?=Z7N:^=L;_YMSOWT(\O"55E%G]%4LTHW<#0
MZON_VK&_TS/\X?WI?:L;_3,_SA_>O"^D?5?K76JK+NFXXNKJ=L>=[&PZ-W^$
M<W\U%ZI]3OK!TG$=FY^**L=I#2_>QVKCM;[6/<Y'[K"^'W1Q=NO_`$D>_*K]
MLUW?<674V&&6-<>8:0?R*:\F_P`5`'_.+(_\*/\`^KI7K*ARX_;GPW;+CGQQ
MXJI8N#1+B`!R2F:]CQ+'!P\096=]9?\`D'-_XL_E"S_J)_R-9_Q[O^IK1&*\
M,LM_+(0X5ASUGCAKYH&?%?;P>C22243,Q;96XPU[7$<@$%27/=!^K61TKJ-^
M79:RQMS7-#6@@C<X6=_@NA3\D8QE4)<8H>JN%CQ3G*-SA[<K/IOB4DDDF,BD
MDDDE/__0]2NIJOI?1<T/JM:6/8>"UPVN:5X?]9>B9'U;ZXZACG!C7"["N'.R
M=U9W?Z2IPV/7N:\;_P`8'UD;UKJ_H8Y#L/!+JZG`?3>3^FMW?N;F[*U9Y,RX
MR!\I'J8.9`X0>MZ.;BT=4^MGU@#7.WY68_=;;'M8P?2?'YM=58]C5[9TWIV-
MTS!IP,5NVFAH:T=S^\]W\M[O>]>)_5WK.3]7.M5Y1:X!A-6701!-9/Z1A:?S
MV?3;_+7N.-DTY6/7DX[Q93<T/K>."UPW-*=SG$#$?H5Z:1RU43^E>J5>;_XW
M_I]+^%__`*)7I"\W_P`;_P!/I?PO_P#1*BY;^>C]?^BOS_S<OHW/\4?_`"5G
M_P#A@?\`4-6C_C-_\2=W_&U?]6%G?XH_^2L__P`,#_J&K1_QF_\`B3N_XVK_
M`*L)\O\`=/\`A!$?YC_!+R/^*C_Q19'_`(4?_P!72O65Y-_BH_\`%%D?^%'_
M`/5TKUE#F_YT^05R_P#-_5S/K+_R#F_\6?RA<?T*WK.9BGI/2W>@W>ZW(R)B
M`X-8UNX>YOT?S%V'UE_Y!S?^+/Y0LKZ@U-'3LBV/<^[:3Y-:V/\`JU+@F(<K
MDE0D1,</%MQ4U.8@9\[CCQ&(.,\7#I+AOY;:&5]7?K%TREV9C9SKC7[GM8YX
M=`Y=M>7-L6Y]6.O'JV*YM\#*H@61PX'Z-@"VB`1!7#_5$>C]9,NAG\V&VM^3
M;&[4!/W\.4S`X\0$HS`X=/THFDF'W;/B&,R]O,3"4)'B%_HRCQ-OZI]0SLGK
M&95D9%EM=;7%C'N)`BP-T']5/U[ZP9^1U']C=&)%F[99:WZ1=^<UCO\`!LK_
M`,)8JOU..WK74'>%;S]U@3?45C;NJ9>39K8&2"?&QTO/_14V3'".3+D,01BA
M#AC7IXY]2&#%DR2Q8<(F0<V28E._5P8]Q$IS]4.O!OK#J9.1$[=UG/AZN[_O
MB-]7?K%FMSCT?J\^N"6UV.^EN'^#LCZ6[_!V+JUPWUR:,?K^+D5>VQS*WD_R
MF/+6G_-:H\.0\P98L@B;B3"0`B82C_=_19L^(<J(YL1D*D!D@9&4<D9?WOTG
MN$DDE1=%_]'H_P#&-]9_V7T_]FXKXS<UI#B.:Z?HO?\`UK?YNO\`MKCO\7GU
M<_:_5QE7LG"P"+'@\.LYIJ_]&/6M]:/^9/[=ROVS^T_MVX;]NS9MC]'Z/_`[
M/YM==]2OV%^PV?L+?]E]1^_U8]7U)]WK1^=MV;?^#5J$P,)CCC(R/S2`8)1O
M(#,@1'RBWC_\:/U<]#(9UW&;^CR"*\L#@6`15;_UUOL=_+_KHW^*_P"LVUQ^
MK^6_0R_!<3W^E;C_`/HVO_KB[CZP_LS]BYG[6_H/IGUO&/S?3_X7?M]+_A%Y
MKA?^-Y]LH^Q_M7[5ZC?0V;-WJ2/3V_VDA,'#PY(R'[DJ_P`5!C^MXH$?UHV^
MMKS?_&_]/I?PO_\`1*]''`7'?XPO^;&[!_;_`-JF+?0^R[?^#]3U-_\`8VJ+
M!+AR1-$[_+J=F3,+@18'FU?\4?\`R5G_`/A@?]0U:/\`C-_\2=W_`!M7_5A/
M_B__`.;WV'*_8/VCT?6'J_:HW;]H^AL_-VJY]=?V1^P;/VSZWV+U*]WV>/4W
M;O9&[^4G2E^OXJ/S#2O5_BH$?U56-CKT?+OJ=]8J/J[U.W-OI?>VRDU!M9`(
M)<Q^[W_U%V/_`([G3/\`ROO_`,YG]ZYO_P!=E_YL_P#H)?\`KLO_`#9_]!39
M)X#*YQD)>/I8X1RB-1,:^UW<[_&7@=5Q+>G5X5U;\D>FU[G-(!/<[5?^I/6,
M;&%N!DO%7J.]2I[C#28V.9N/]5<SB?\`C;?::_2_:7J;AMG9$^:Z2[_F?^QJ
MY]>/4?Z/T?7G3?\`R/1_XQ.$\'LR@(SX)2%S`^0M?)CS_>89!*''&!J$C1F/
M+_NGJ>I]9P>G8K[[+6N<`?3K!!<YWYK6A<[]1<.Y]N3U.T:/_1L<>Y)]2T_]
M2L;$'U3%P]=^8YD\.;6UO]OT7OL_S%Z'A?9/LE7V+9]FVCTO3^CM\E&90ABG
M##Q9.*O<R</#&,`O$<D\^.>?@Q"%^UCXN*4YGJ\A]3/^7,_^H_\`\^!`P;3]
M6OK);3E`MQKI;O[>FX[ZK?['T7K7^K?["_:F5^SOM'VC:[UO5C;&\;MFW^6K
MGUF_8/V5O[7YU]'9_.SW]*/^_?HU+/-^MR<4)^U.$8Y/34H?NS888/U6+AR0
M]Z$YSQ>KBC/]^#I'J&"*?7.17Z43OWB(^,KBK;'?67ZSUF@$XM):-Q'^"K.]
MSW?\:_Z*S@WZK>I)?G;/#93/^=ZG_?5V_P!6_P!B?8S^R(VR/5W?SF[_`(;=
M_P"<*/&<>/B.$RRY9`B/IK@'Z4F7+'-EX1G$,&&,A*7KXO<D/EBZR2=)4V^_
M_]G_[1%\4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``````````````````
M````.$))30/M```````0`&`````!``$`8`````$``3A"24T$)@``````#@``
M```````````_@```.$))300-```````$````>#A"24T$&0``````!````!XX
M0DE-`_,```````D```````````$`.$))300*```````!```X0DE-)Q``````
M``H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F
M9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T````&
M```````!.$))30/X``````!P``#_____________________________`^@`
M````_____________________________P/H`````/__________________
M__________\#Z`````#_____________________________`^@``#A"24T$
M`````````@`!.$))300"```````$`````#A"24T$"```````$`````$```)`
M```"0``````X0DE-!!X```````0`````.$))300:``````-)````!@``````
M````````+0```)$````*`%4`;@!T`&D`=`!L`&4`9``M`#$````!````````
M``````````````````$``````````````)$````M````````````````````
M``$`````````````````````````$`````$```````!N=6QL`````@````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<````M`````%)G:'1L;VYG````
MD0````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````
M!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN
M96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E
M96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````+0````!29VAT;&]N9P```)$````#=7)L5$585```
M``$```````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A
M;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L
M;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R
M>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V56
M97)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L
M:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````````
M``IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``````
M```+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_``````
M```X0DE-!!0```````0````".$))300,``````NG`````0```)$````M```!
MM```3*0```N+`!@``?_8_^``$$I&248``0(!`$@`2```_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"``M`)$#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#U%V10UQ:ZQC7#D%P!7)?XPOK3F]'PL:OI;PRW
M,<\'($.VMK#=S63N9ZCO46;_`(T/JR+*QU_%9[ZP&9H`Y;Q5?_UO^;L_D+G?
MJ6_IW4GN^K75P3BY;O5Q+`=KJL@"/T3O^[%?M5G%BCPC+?&(_-"F#)DE9A\I
M/RR>B_Q=_7#JW4,^WIO4[?M+?2==7>X`.9L+=[7N:&[F.WKOOM.,=!:R3_*'
M]Z\N^M^+TCZJX;NB=)+W9?4`'9M]CMSQ0#-='M#&L;=8/^@F_P`6OU7&?F_M
MC+9.+ANBAI&C[A^=_5H^E_QJ.3%"43E'HC^C&OF5"<@1C/JEU-[/J9R<=I+7
M6L!&A!<)3?:L;_3,_P`X?WKRKK_U$^L^;US/R\?##Z+\BRRM_J5B6N=+7;7/
MW+G>L?5WJW1#4.IT"CU]WI>YKYVQO_FW._?0CR\)5646?T52S2C=P-#J^[_:
ML;_3,_SA_>E]JQO],S_.']Z\+Z1]5^M=:JLNZ;CBZNIVQYWL;#HW?X1S?S47
MJGU.^L'2<1V;GXHJQVD-+][':N.UOM8]SD?NL+X?='%VZ_\`21[\JOVS7=]Q
M9=38898UQYAI!_(IKR;_`!4`?\XLC_PH_P#ZNE>LJ'+C]N?#=LN.?''BJEBX
M-$N(`')*9KV/$L<'#Q!E9WUE_P"0<W_BS^4+/^HG_(UG_'N_ZFM$8KPRRW\L
MA#A6'/6>.&OF@9\5]O!Z-)))1,S%ME;C#7M<1R`05)<]T'ZM9'2NHWY=EK+&
MW-<T-:""-SA9W^"Z%/R1C&50EQBAZJX6/%.<HW.'MRL^F^)22228R*22224_
M_]#U*ZFJ^E]%S0^JUI8]AX+7#:YI7A_UEZ)D?5OKCJ&.<&-<+L*X<[)W5G=_
MI*G#8]>YKQO_`!@?61O6NK^ACD.P\$NKJ<!]-Y/Z:W=^YN;LK5GDS+C('RD>
MI@YD#A!ZWHYN+1U3ZV?6`-<[?E9C]UML>UC!])\?FUU5CV-7MG3>G8W3,&G`
MQ6[::&AK1W/[SW?RWN][UXG]7>LY/U<ZU7E%K@&$U9=!$$UD_I&%I_/9]-O\
MM>XXV33E8]>3CO%E-S0^MXX+7#<TIW.<0,1^A7II'+51/Z5ZI5YO_C?^GTOX
M7_\`HE>D+S?_`!O_`$^E_"__`-$J+EOYZ/U_Z*_/_-R^C<_Q1_\`)6?_`.&!
M_P!0U:/^,W_Q)W?\;5_U86=_BC_Y*S__``P/^H:M'_&;_P").[_C:O\`JPGR
M_P!T_P"$$1_F/\$O(_XJ/_%%D?\`A1__`%=*]97DW^*C_P`461_X4?\`]72O
M64.;_G3Y!7+_`,W]7,^LO_(.;_Q9_*%Q_0K>LYF*>D]+=Z#=[K<C(F(#@UC6
M[A[F_1_,78?67_D'-_XL_E"ROJ#4T=.R+8]S[MI/DUK8_P"K4N"8ARN25"1$
MQP\6W%34YB!GSN./$8@XSQ<.DN&_EMH97U=^L73*79F-G.N-?N>UCGAT#EVU
MY<VQ;GU8Z\>K8KFWP,JB!9'#@?HV`+:(!$%</]41Z/UDRZ&?S8;:WY-L;M0$
M_?PY3,#CQ`2C,#AT_2B:28?=L^(8S+V\Q,)0D>(7^C*/$V_JGU#.R>L9E61D
M66UUM<6,>XD"+`W0?U4_7OK!GY'4?V-T8D6;MEEK?I%WYS6._P`&RO\`PEBJ
M_4X[>M=0=X5O/W6!-]16-NZIEY-FM@9()\;'2\_]%39,<(Y,N0Q!&*$.&->G
MCGU(8,63)+%APB9!S9)B4[]7!CW$2G/U0Z\&^L.IDY$3MW6<^'J[O^^(WU=^
ML6:W./1^KSZX);78[Z6X?X.R/I;O\'8NK7#?7)HQ^OXN15[;',K>3_*8\M:?
M\UJCPY#S!EBR")N),)`")A*/]W]%FSXARHCFQ&0J0&2!D91R1E_>_2>X2225
M%T7_T>C_`,8WUG_9?3_V;BOC-S6D.(YKI^B]_P#6M_FZ_P"VN._Q>?5S]K]7
M&5>R<+`(L>#PZSFFK_T8]:WUH_YD_MW*_;/[3^W;AOV[-FV/T?H_\#L_FUUW
MU*_87[#9^PM_V7U'[_5CU?4GW>M'YVW9M_X-6H3`PF..,C(_-(!@E&\@,R!$
M?*+>/_QH_5ST,AG7<9OZ/((KRP.!8!%5O_76^QW\O^NC?XK_`*S;7'ZOY;]#
M+\%Q/?Z5N/\`^C:_^N+N/K#^S/V+F?M;^@^F?6\8_-]/_A=^WTO^$7FN%_XW
MGVRC['^U?M7J-]#9LW>I(]/;_:2$P</#DC(?N2K_`!4&/ZWB@1_6C;ZVO-_\
M;_T^E_"__P!$KT<<!<=_C"_YL;L']O\`VJ8M]#[+M_X/U/4W_P!C:HL$N')$
MT3O\NIV9,PN!%@>;5_Q1_P#)6?\`^&!_U#5H_P",W_Q)W?\`&U?]6$_^+_\`
MYO?8<K]@_:/1]8>K]JC=OVCZ&S\W:KGUU_9'[!L_;/K?8O4KW?9X]3=N]D;O
MY2=*7Z_BH_,-*]7^*@1_558V.O1\N^IWUBH^KO4[<V^E][;*34&UD`@ES'[O
M?_478_\`CN=,_P#*^_\`SF?WKF__`%V7_FS_`.@E_P"NR_\`-G_T%-DG@,KG
M&0EX^ECA'*(U$QK[7=SO\9>!U7$MZ=7A75OR1Z;7N<T@$]SM5_ZD]8QL86X&
M2\5>H[U*GN,-)C8YFX_U5S.)_P"-M]IK]+]I>IN&V=D3YKI+O^9_[&KGUX]1
M_H_1]>=-_P#(]'_C$X3P>S*`C/@E(7,#Y"U\F//]YAD$H<<8&H2-&8\O^Z>I
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M%ZN*,_WX.D>H8(I]<Y%?I1._>(CXRN*ML=]9?K/6:`3BTEHW$?X*L[W/=_QK
M_HK.#?JMZDE^=L\-E,_YWJ?]]7;_`%;_`&)]C/[(C;(]7=_.;O\`AMW_`)PH
M\9QX^(X3++ED"(^FN`?I29<L<V7A&<0P88R$I>OB]R0^6+K))TE3;[__V0`X
M0DE-!"$``````%,````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'`````2`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3
M`````0`X0DE-!`8```````<`"`````$!`/_A%_EH='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP
M0V5H:4AZ<F53>DY48WIK8SED)S\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O
M8F4Z;G,Z;65T82\G('@Z>&UP=&L])UA-4"!T;V]L:VET(#,N,"TR."P@9G)A
M;65W;W)K(#$N-B<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW
M,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT
M='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70])W5U:60Z.30P,&9B9&,M9#(V-"TQ,64P+6(V-C(M.3(Y
M-3@R9CAA-35D)PH@('AM;&YS.F5X:68])VAT='`Z+R]N<RYA9&]B92YC;VTO
M97AI9B\Q+C`O)SX*("`\97AI9CI#;VQO<E-P86-E/C$\+V5X:68Z0V]L;W)3
M<&%C93X*("`\97AI9CI0:7AE;%A$:6UE;G-I;VX^,30U/"]E>&EF.E!I>&5L
M6$1I;65N<VEO;CX*("`\97AI9CI0:7AE;%E$:6UE;G-I;VX^-#4\+V5X:68Z
M4&EX96Q91&EM96YS:6]N/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z.30P,&9B9&,M9#(V-"TQ,64P
M+6(V-C(M.3(Y-3@R9CAA-35D)PH@('AM;&YS.G!D9CTG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R<^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HY-#`P9F)D8RUD,C8T+3$Q
M93`M8C8V,BTY,CDU.#)F.&$U-60G"B`@>&UL;G,Z<&AO=&]S:&]P/2=H='1P
M.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O)SX*("`\<&AO=&]S:&]P
M.DAI<W1O<GD^/"]P:&]T;W-H;W`Z2&ES=&]R>3X*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.CDT,#!F
M8F1C+60R-C0M,3%E,"UB-C8R+3DR.34X,F8X834U9"<*("!X;6QN<SIT:69F
M/2=H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R<^"B`@/'1I9F8Z3W)I
M96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*("`\=&EF9CI84F5S;VQU
M=&EO;CXY-B\Q/"]T:69F.EA297-O;'5T:6]N/@H@(#QT:69F.EE297-O;'5T
M:6]N/CDV+S$\+W1I9F8Z65)E<V]L=71I;VX^"B`@/'1I9F8Z4F5S;VQU=&EO
M;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.CDT,#!F
M8F1C+60R-C0M,3%E,"UB-C8R+3DR.34X,F8X834U9"<*("!X;6QN<SIX87`]
M)VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX87`Z0W)E871E
M1&%T93XR,#$Q+3`X+3(Y5#$S.C,P.C0T+3`U.C`P/"]X87`Z0W)E871E1&%T
M93X*("`\>&%P.DUO9&EF>41A=&4^,C`Q,2TP."TR.50Q,SHS,#HT-"TP-3HP
M,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A=&4^,C`Q,2TP
M."TR.50Q,SHS,#HT-"TP-3HP,#PO>&%P.DUE=&%D871A1&%T93X*("`\>&%P
M.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD;W=S/"]X87`Z
M0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TG=75I9#HY-#`P9F)D8RUD,C8T+3$Q93`M8C8V
M,BTY,CDU.#)F.&$U-60G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E
M.F1O8VED.G!H;W1O<VAO<#HY-#`P9F)D8BUD,C8T+3$Q93`M8C8V,BTY,CDU
M.#)F.&$U-60\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO
M;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HY-#`P9F)D
M8RUD,C8T+3$Q93`M8C8V,BTY,CDU.#)F.&$U-60G"B`@>&UL;G,Z9&,])VAT
M='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\9&,Z9F]R;6%T
M/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_
MX@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"
M``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'0@``````````````````]M8`
M`0````#3+4A0("``````````````````````````````````````````````
M`````````````````!%C<')T```!4````#-D97-C```!A````&QW='!T```!
M\````!1B:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:
M```"0````!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V
M:65W```#U````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,```
M``QR5%)#```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT````
M`$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``
M9&5S8P`````````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````````````````````````````````
M````````````````````````6%E:(````````/-1``$````!%LQ865H@````
M`````````````````%A96B````````!OH@``./4```.06%E:(````````&*9
M``"WA0``&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H
M='1P.B\O=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE
M8RYC:```````````````````````````````````````````````````````
M``````!D97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````
M````````9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````````
M`````````'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A9
M6B```````$P)5@!0````5Q_G;65A<P`````````!````````````````````
M`````H\````"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9
M`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`
MBP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[
M`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!
MD@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+
M`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#
M.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(
M!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%
ME@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'
M!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(
MO@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8
M"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,
MP`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)
M#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1
MJA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J
M%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47
MB1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%
M&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>
M:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G
M(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F
M5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;
M*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O
M6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K
M-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y
M?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@
M/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$
MSD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$
M2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[4091
M4%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@
M6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?
M#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]
M9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN
M$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A
M=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^
M8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7
MASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0
M!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DD
MF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C
M!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0
MK42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W
M:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'C
MPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7-
M-<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-AD
MV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD
M<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8
M\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]
M*?VZ_DO^W/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#
M`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"``M`)$#`1$``A$!`Q$!
M_]T`!``3_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!
M`0$````````````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01
M!1(&(0<3(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3
M-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*
M6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)
MRM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A
M$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&B
MLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%
MU>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)
MF:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?*K^P-AXJMJ,=
ME-[;1QN0HW6.KH*_<F&HZVED:-)52HI:BMCG@=HI%8!E!*L#]#[=$$[*&6%R
MIX&AH>F&NK9&9'N(PXX@L`1YY%?3K7D_X4(_S1NZ/A/TKT=MSXG[EQ>#WE\@
M=R;\HZSN+&TN!W:FT=N=<T6W7RV(VTF0I\OMX;JSU?NRF'GGBF:CI*:8I&)7
M22*9/9GD':^<=XW27?E+65BD9,-2ID:77I+4HP1?#-:$$DC-*@QO[D<W7FP;
M;9C:7`GN&<>(*,%"::@<0&.L4.:4(XFH)1_PGC_F_?*[Y*=];^^+?RNWY4=P
M89>J]P]K[-[.W!C<#B]Q[*?9F5PE)N#$[FS&&H,-1Y/;.6H=Q++#45D;3T=3
M3!!*8IM,8I]ZO;;E[ES;;'F#EZ`6^J<0O"&)5BZLRL@:I!&@@@&A!J`*=$7M
MISONN\WMSM>[2^*HC+JY`!732H8^:T-:FI!H.!QMTQ]F=<321Q1=@;(EEFDC
MAACCW7@7DEEE=8XHHT6O+/)+(P55`)8D`<^\<_IY\GP'H/Z)_P`W4R"[M20!
M<QU/](?Y^LU7V)U_05510UV^MG45;23/3U='5[GPE-54M1$=,D%13S5R2PS1
MMPRL`P/U'O0@G(!$+T(]#UMKJV4E6N(PP.06'^?J/_I/ZT_Y^'L;_P!"W`?_
M`%P][^GG_P!\/^P_YNM?66G_`"E1_P"]+_GZ]_I/ZT_Y^'L;_P!"W`?_`%P]
M^^GG_P!\/^P_YNO?66G_`"E1_P"]+_GZ]_I/ZT_Y^'L;_P!"W`?_`%P]^^GG
M_P!\/^P_YNO?66G_`"E1_P"]+_GZ=,1O/9^X*EZ+`[KVUFZR.%JAZ3$9W%Y*
MI2G5TC:=X*.JFE6%7D52Q&D%@+\CW5XI8QJ>-@M?,$=72X@E.F.9&:G`$'_`
M>E+[;Z=ZC5E;1X^FFK:^KIJ&CIT,E15UD\5-301@@%YIYF2*)`3]6('NR(\C
M*D:EG/``5)^P#IN::&WC>:>54A45+,0`!\R:`?GU@QN6Q>8@:JQ&2Q^5IDE:
M%JC&UE/70+,BJSQ--322QB55<$J3<`C^ONTL,L#:)HF1Z5HP(-#P-#Y=-VUW
M:WD9EL[F.6(&E48,*CB*J2*BO#IP]M]*.O>_=>Z9<?N3;N6J):3%9["Y.K@5
MWGI<?E*&MJ(4CD$3M+!33R21JDI"DD`!N/K[>DMKB%%DF@=$/`E2`?/!(SC/
M2.#<=ONI7AM;Z&2914JKJS"AH:@$D9QGSQT]>V>EG7O?NO=>]^Z]U[W[KW7_
MT#J?\*@/Y9T.X\#0?S&>I-LQRY[:E)B=G?)K'8VD,DV4VC')%C=D]K30Q0L7
MJ=IS3)B<M,3<XV6CE:T='(WO(_V%YS2VNY.3-S9?IYV+VQ;\+Y+Q"O\`OSXU
M&!J##BP'4*>Z_+#SPKS%8H?%2BS`5RN`KT'F,(QH333P`)ZII_DPY?X[?)[,
MYK^5K\SZ*MJ^F>]]S?Z1OCUNS$YQ-M;JZ?\`DMB,-)CJM=D9V2GJJ?'GMW9L
M)H:BEJ(JBBKJ_'4D3T\DDX829[J6.\\N&#W#Y38)N%JGA7"::I+;L:@R**:O
M#<CT8*S,&%.@/R'<;?O'C\H[_P!UG</KA:O='*!3M)J.X`"AP6"BG1M?YO/5
M_P`1OY1'3V7^"'PVGW9F>\OE?B<9FOD_VEOS<M'N3?V%^/N%S"5^U>J8*G$8
MK`8;;F([(W50-4U5)24<,M7C\8_WC3)44Q0/>W%WS'[G;TG-O-?AC:-M8BVA
MC0K$9V'>Y5F8L8U(RQ;N8:""K#HZYSBV;D?;'Y?V-G.X78_5D8@NL8.I4!4*
M!J:A-!72!JJ"*1O^$UG\L"D^1'=$GS;[@VO#5=,_'W<24W5&+RE%$V/[`[RH
M$AK(LQX98R*S!]313PUFJP23.34H!;[2HC]Z]\>>H]KV\<J;2P3<+M*S,M`R
M0&HTXX&;(X_`K5'<#TW[5<KRW]ZV_7ZDV<#4C!X-)QK]B5!X?$5H>("7^??\
MBG^9QWC\X/EKW)UK\;<;N'KWM#Y`=F[XV5GI>U^G,3)F=L[AW+6Y'$9*3&9C
M>U%E:!ZNDF5S%4PQ3(39E!]J.2_=CV]V?E+EW:]SOY%W""TC20""5J,J`$:@
MI!I3R-.F>9N0N;]RWW=KZSL2;:2XD93XD8JI<D&A<$5!KD#JFSY@_P`NSY7_
M``+EV!!\J.J:'K:7L^/<DNR%@WAL7>'\83:389<^6;9F>SJX\T)W!2<5!B,G
ME]&K2UI1Y7YTY2YR>\3E^X,K0:=>J)HZ:]6GXU%:Z6X5I3-*CH`[[RYO_+8M
MCNT)C\;5I[U:NFE?A8T^(<>E)\1/Y7WS/^=NU-V[V^+G3F/['VUL;<D&TMSY
M"??/7>T&QV?J<739J&B6DWEN/!5=8KXVLCD\L*21#5I+!@1[:YFY\Y-Y/NK>
MSW^Y,5Q+'K4+"[]M:5JBD#(Z?V3E3F3F&VDNMJMS)"C:2=:BAI7@S`]+7Y._
MR>_G[\.>I<GWC\B.A\;L3K'#Y?`X+([BB[&ZMW.\&4W+D(\5A:<8C:VZ\QEY
M15U\JQEU@*1WNY`Y]H]@]RN1.9]SAV?9;MI+]U8A3!(@(4:FRR`8`)X]*-UY
M*YJV6RDW#<;0I:J0"=:'CPPKD_RZM'_X2C00K_,-[=98HU;_`&4G>HU*BJ;'
MM3J`$74`\^P#]XR../DW:&1`#^\TX#_A$_0K]G)';F2\5F)'T;_\?BZ^A3[P
M\ZR7Z([_`#*D5_@C\G5=0RGK.ONI%P;5^.(N#_0CW*WL::>[WM[@$?O*/CGB
M&'#J#_O)DK[%>YI!H?W:W_'TZ)Y_(D55^&^ZM*JM^^=ZDA0%!/\`=38`OQ^;
M#W*GWPD1/=>S5%"K^YK;``'^B7'IU#GW#S7V7W+Y;]=?]6;7JZ7WBKUFGUTU
M[&WU_P!>W^\_CW5QJ1@.)'V=>ZIZ^!?\MKL+XC?(;M/N;='86QMU8KL#;FYL
M)1XG;F,S=%DZ&;.[XQ6ZH9JN?)1K32104N.:)PA+&1@1P#[R4]W_`'QV?W)Y
M#Y2Y3L.7Y[6]V^:)Y)7:,K)X=N\+`!%#9+:A4^5.L0O8O[N','M+[C<V\Z[E
MS+:WEEN-O-&L4:R*Z&2XCF#$MVT`0J0*FIP<9N&]XV]9>]>]^Z]U[W[KW7O?
MNO=?_]'?4WCM#;/8.TMS[$WIA*#<NS]Y[?S&U=T[>RD(GQN<V]G\?48K,XBO
MA)'DI,CCZJ2*07!*N;$'V];W$UK/#=6TI2XC<,K#!5E-00?4$5'34T,5Q#+;
MSH&A=2K`Y!4BA!^1&.OE??S*/A5V#_*Z^;^:Z\P62S>/V_B-P8ON#XT]BT[5
M,%?5;)3/'*[.KJ?*,JB3=G7V:QW\-KV4EOO*$3V$=1%?/OD/FFS]Q.4UFNHU
M:<(8;F(TTE]-&)`X(X.I1Y`T!-#3$/F[8KGE'F*2.`L(-0DA?/"M0*_Q+2A/
M\0)`'2;ZQV-\G/YQ/S]I,3E<X<_W/\B-Y#-]@;XDQ\@V]L#9>'I*6+.[E;&P
MN8<7M386TJ!(,?0*ZK(\=-1QMY9E)4;C=;%[6\F22P0Z+"VCTI'J[I9#72*G
MB[L:LWD-34`&&;&WW3GOF9%FD#7,\E7:E%50,D@>2J*`>>%&:=?48^-?QZZV
M^*?1?6?Q[ZCPZ878/5VV*';>%A*Q?>Y"6$-/EMP9F:)(UK,_N7,3SY"OG(!F
MJZF1^+V&!&\;O?;]N=[N^Y2Z[R>0LQ\A7@H]%4451Y``9X]9;[5MMMM&WVNV
MV::;>)=(]3ZL?FQJQ^9Z''V6]&'6E!_PKT_XO'P,_P"U?\BO^M_3?O*#[MO]
MKS=]EK_VL=0+[V\.7O\`F]_UBZ,A_P`)(O\`LECY7_\`BQ6#_P#?6[8]DGWB
M/^5BV/\`YY'_`.KK=&_LS_R1-R_YKC_CO1T?^%,O_;J+LK_Q+/1O_O?X[V&/
M8W_IX>W?\T9O^.'H_P#=/_E3K[_3I_AZUV/^$H__`&\,[=_\5*WI_P"_5Z@]
MS1]X_P#Y4S9_^EFG_5B?J*?9K_E9;S_GCD_X_%U]"7WASUDUT1_^9/\`]D)_
M)S_Q&>0_]S\?[E7V._Z>][>_]+*/_+U!_P!Y3_IQ/N=_TK&_X^G6MY\$]T?,
M7NCK*;X:_$S,)UCCQN[<7:7;G<`RM7AZG'8?/T.!P&(P@S5#25.5P]*\F$<B
M+'(V0KYG-GAIX9BV=?O5M?MARIS.ONE[F6QW*9K.&UL=O"A@\D32222.K'PW
M`#J/U/TT\PS,H'-KV`WCWBYWY4E]F?:2Z&U0"]FO=PW(NR%(IEBBCC5T'B1_
MV;$>%^K(QXJB,>C+=J?R\?YB7Q5VEG>[>JOE5NCL&NVI3U&Y-S87;&[.P:#<
M3XV@BDJLADZ7![CR>;P>\(J&G622HI*@>66('1'*WH,=\O>]7L)[A;E8\I<U
M^UEIMUK=.(XY6BMS$KL0J*TL21RPZB0`ZU`/%E&>I0YL^[U]XWVKV>\YVY4]
MW+S<IK)3--%%-<K*8U&IW$4C21W`4`LR-DBM%8XZM,_EB_.ZJ^975N9QF_8<
M=1]R=:/C*#>(QD24V/W7B,K%,<+O:@QZ>G'BODI98*VG2\,-5%JCTQ31QIC[
M]X3V=3VGYDB&URO)RK?J[6Q?+1LG]I;NV=9CJK*^"R,*C4">LI?NP>_+>]7*
MMY#O<<<?..V%$N0E`LR/7P[A4_!K*LDB"H61:B@=54C'\J#O[O#M3Y@?)3:7
M9?;6_P#?FU]K[9W=5[>P&Z=R9#,8G#5-)VOC,533XVAJY9(*66#&2M`A0`K$
MVD<<>Y:^\C[?\D\K>UOMSO'+O+-G9;G<W,"RR11A6D5K-F8.1D@N`V?Q`'J"
M_NH^X?//-GO)[F[/S+S9?WVU6EK<&&&:9Y(XV6^B161&)"D(2HH!@D>E)GSO
M_F`=^=D_(:+X0_"&HJZ'=8SHVANS?&$>FCS^2W4L+3YG`[>S-0)*;:NW]H4R
M2-ELJ--0DD$RI)%'`QF][.^RG).S<BO[Q>\8#[(8C-;VS@Z!%72DDJ"AFDG:
M@@ARC`JSJVH`*??K[P/N!S#[AQ^Q?L:SQ[X9_`N+N,J)3,!JDCB<X@B@4'QY
M\2!E8*45"72DO\HOYVTV.DWO1_-_(S=J?9FJ;&KO#MNGIIJ]4\@H%WT^X7K6
M#LH02OBUC)M=0O(6#[R'LU)(-ID]E(%Y?+Z=7A61<)6FHP^$%K3)42\.!KCH
MHE^Z/[^+;-O47OU.W-(34%,]\`7`KI^I\77Q%`3%I\R*="%_+O\`YAG=..[M
MJ_A3\TC7OV3!EZ[;>T-Y9R"EI]PQ[HQL#5`V5O">CBCH\V,W1H9L1EU):J)1
M'>?[B&0%?O?[(<H'D^'W?]HF7^J[1K+/;IJ*".0Z?'A#'7'H<A9X"*)W,-&A
ME(B^[M]XCG.'GBY]D/>LO_6J.5H;>YDTB4S("?IYRM%D\11J@GRSFBL7\167
M8"\@_P!2_P#R2?>&.H==`/S'7__2W]V8*I8D`*"220``.223P`![T>!Z\>OF
MH?\`"@#^8YC?G;\MH]A=9U5#DNA?C%4[DV#L'-TE'2/-OO>V1K:.F[(WO2Y2
M-)*RJV[79/!TV.Q$2R&GFI:`5BKJJ_3G%[+\D2\I<O2;CN*,F[7ZK(ZDFD<:
M@F)*?Q@,S/4`@MI\NL5?<OF8<P[T+.TTM8VM44C\3$]S`^88@:?D`:Y/1*/Y
M=_S*[)_ED?-/:G;M7@]P45'MS*5O6_R`ZPR-'58K-YGKS(Y"EI]Z;:K<371T
M]31[IVW5T,62H(IU1H\ICXDDLC2`BKGSE>R]P.4Y;&":-G(\:VE!!7Q`IT,"
M,%'!*D_PL2/7HBY5WVZY2WZ*>6(J`WARHV#H)&H&O`@@$<*,HK@$=?52ZW[$
MV;VYL#9G:/7>?H-T[$[!VSA=X;0W'C)/+0YG;NX<?3Y/%5\#&S()Z2I4LC!7
MC>Z.`RD#GY=VMQ8W5S97<+1W4,C(ZG!5E-&!^PCK,"VN(KNWAN8'#02*&4C@
M014'I:^T_3_6E!_PKT_XO'P,_P"U?\BO^M_3?O*#[MO]KS=]EK_VL=0+[V\.
M7O\`F]_UBZ,A_P`)(O\`LECY7_\`BQ6#_P#?6[8]DGWB/^5BV/\`YY'_`.KK
M=&_LS_R1-R_YKC_CO1T?^%,O_;J+LK_Q+/1O_O?X[V&/8W_IX>W?\T9O^.'H
M_P#=/_E3K[_3I_AZUV/^$H__`&\,[=_\5*WI_P"_5Z@]S1]X_P#Y4S9_^EFG
M_5B?J*?9K_E9;S_GCD_X_%U]"7WASUDUT1_^9/\`]D*?)O\`\1G7_P#N?CO<
MJ^QW_3WO;W_I91_Y>H/^\I_TXGW._P"E8W_'TZK^_D';6H*+X]=R;O6!1E,_
MW(,)4U)TF1Z#;.R]NU./I[_58X:C<E4X'^JE/N:OOF[E-=>X/+.W.Y\&VVA6
M"^6J::0LU?F$4?[4=8^?<`VN"'VSYMWD1+]3<[R8RP\T@@B*K]@:5R/]-\NK
MW)XXYHI(ID22*53')'(H=)$D&AXW1@59'4V(/!!]X>R:]#:"0WRX]9Y$*PHP
MJ#UJO?RBZ=]D?S(/D-L#!"?^[=+M[NC`,C'A*#:':V$IL$TZH!$9(D30IL+:
MV`X)]]#OO/R#>O8#VYWV]`;<&DLY-7`ZIK*0R4^1/E^?7*O[G\0V/[RON7R_
M8EAML=MN$6GR"P7T*QU^8`ICS/ITZ_R=:LX_YG_,.O6-Y6H=A=AUJQ1H9'D:
ME[=QLZHB*"SNYCL``23[I]ZN/QO9_P!IXJTU7ML*^E;)ATK^YK(8O>_WDE`J
MR6-VP'S%_$?\G4?^1GB:/?/R>^0?9^X4-=NK'['FK:2LJ0&GAK^Q-[3UVXJX
M:E#+5S_POQ,W!T32*?U>_?>\E?:?;SD#ENQ8IM1N:%1P(MH`D8)_A`<D#A45
M\NF?N*VB;][I>Y?-FZ?J;Q':&C,:D-<W):5J<*G10GT8CS/6TS[Y[]=4.M57
M^<911=:?/OH;LK:(3&[KR6T^M-X5E;$;23[@V?V/D\9B,A,JD79<;BZ:G)MZ
MHX`#]/?0W[KM-]]D_<#ES=29-I$UW&$/`+-:!Y%!\JL68CR+5&2>N4_WR8UY
M9^\-[<<T[.@CW=[6SG9A^*6"[D2-C\PL:+\PH'`=;4VM?ZG_`&Q_XI[YV:&_
MC_P==6-0]/\`#U__T[J?^%&/\SD_$KX^#XM=1[A2C^0WR4V_DZ'+5V.JM&5Z
MSZ3J6FQ.Y=S7B834&=WRZSX;$/Z71%KJJ-EDI8BTT>R_(1YIWS]\[A&3LE@X
M)'E)-@HGS"BCO\J+G5U%_N;S8-BVO]W6D@_>5TI'S2,X+4]6/:/EJ(X#K6U_
MX3S_`,NC_9SOEW2]M=@X%:[X]_%BLP.]]S05L&O%[R[/,S5O6>P=$J-#6T5%
M5T+9K*1'5&:2BAIY1IK5]SC[V\[MRUR]^Y+%R-VOU*@C\$/"1J\02#H'^F+#
M*]15[7<L_OS>?WC=J6LK4AC7@SYT@^1!(J?]*011NCW_`/"H?^77_<#L3;W\
MP7J_!LFTNTZW%[$^0=)CZ:-*7!=C4E%'1;(W_41P!?'!OK$TG\,KI2H49*AI
MW=C+6L?83]@N=VFMY>2[]ZR15DMR3GPR:R1_/2Q+KYZ68?"HZ$?NYROX4\7,
MEHE$D.F6@X,!VMC^(#-<57U;H1?^$P7\R]<;6UO\N3N'/A:3(2YO>7Q=RV4J
MG"PU[BJS>_>GXY9B8UCJE2;.X6*Z_N#(0@DM31^R_P!^N03$PYWVN(E6(2Z4
M>1J%2;TIP1AQ%%/`D]*O:7FS4IY:OINZI:`FGH2R?RU#YUSD#K=E]XQ=3QUI
M0?\`"O3_`(O'P,_[5_R*_P"M_3?O*#[MO]KS=]EK_P!K'4"^]O#E[_F]_P!8
MNC(?\)(O^R6/E?\`^+%8/_WUNV/9)]XC_E8MC_YY'_ZNMT;^S/\`R1-R_P":
MX_X[T='_`(4R_P#;J+LK_P`2ST;_`.]_CO88]C?^GA[=_P`T9O\`CAZ/_=/_
M`)4Z^_TZ?X>M,G^3K_,3V-_+.^2V]N]=_P#7&\.SL3NGIC.]7TF"V5DL'C,G
M1Y++[QV3N:/*U,V?EAI)*"*FVK+"R(PD\DR,+J&'O)_W3Y'ON?=CL=IL;V*!
MXKL3%G#$$+'(E!I!-27'4"<B<SVW*NZSW]U`TBM`R``TR60UX'^'K95_Z"XO
MC7_WB'WY_P"A;UK_`/7/W!8^[GS"1_R7K0?[63_-U*_^O1M'_1KF_P!Z_P"A
M>@J[O_X4K]#?+CJC>_QJVW\9NY=HY[N;#/LK%;FS^Y=AU6%PM975$$\=;DJ?
M&5TU?-2QBF(*Q*7)(_U_8]]K_8S>N7?</D[>KC>K62&WOD<JJR:FI7`J*5/S
MZB;WV]TMLWWV=]Q-KAVZ599=M<`EA0493Y@>GKT:[^2;\P.MNJXM^?'?M+<N
M,V1_?'=%/OO8&XMQ5D.-P&4RU1BJ/;^;VO4Y2LDBHL=D9TQ-+/1&5DCJ&$T0
M;RB-''?WN?;+?=\NMFYZY>M'NXK6U^FNHXUU21*K&2.72M6=:.RO0$H"C4TD
MD8[?<:]X>6.5X.8/;CF?<XK&6\NA=6DDS!(Y'*+%+"7:BJY"(R:B-=&6NK2#
M>C\F?F7TA\:NKL_O_<V^=KY'(PXRM_NAM'$Y[&9#<.\MQBE>3%X?$8VDJ9:B
M2.>I\9GJ2H@I8"TDC``7P\Y&]M.:_<#?[+8]HV>?PGD433,C+%;Q:@'DDD(T
MK05TI76[#2H)ZSS]S?>+DGVQY6W'F+>-\MVG6)O`@21'FN)M)\..-%))U-34
MY&A%JSD#C3;_`"+NG-V9G=G>/RNW532?:;E2IV'M[)U(D\F:S>5W!#N[L#(T
MC2+:>DI*NFHJ<S!B&F>5/U1O;*3[XG-6VVNW<F>UNTG-B@GF0'^R18C!:HWF
M'*&1BI_"5;@0>L,?N)<F[O?[MSW[O;Q;E4O2UM"[5!E=YA/=,H/X598U+>;%
ME&5;I`_R9%5OG!\M%9=:OL_?",G^J5NY<2K+_P`A`V]B'[V-?]9GVMIQ^KM_
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MR:R1PS4#[[W%5ST]!#*1.5K(%9599`F?UCMY^[I]W?=TY@E5.<-T64B,,"1=
M7$?A1QI3!^GB`DE*U!*,`:$=<O\`==PF^]3]Z;9).7[9Y.1=J>$>(5(7Z*VD
M,LLKU`*_4REDA5A7]2,$`AJ;:>H_ZAO?-_2/X#^W_9ZZU5;TZ__4&3^:#_PR
M=_L]'??^SQ?\.>?[,5_>*B_O+_"/[@?W+_N]_":+^Y?^C/R\?Z-?[M^#^$V]
M?BU>?_*O/[RB]O?]=/\`JGMO]4OW/^YNZFK7XFK4=?B?T]5:^7"F*=0/SE_4
M7]_WO]8/WE^\*BNGP=%-(TZ-6=.FG'/KGK8G_DI_[(M_LCVWO^&_/[Y_Z&O[
M_;\_O#_I1^S_`-+7^D?^)0_QW_23]C_DO\8_@W\.^Q\7[7\%^RT<>X9]R?ZV
M?UKO/ZXZ/WIH2FBOA^'3M\*N=&K76N=>KJ2.2/W#^XHOZNZ_H-;5UTUZ\5UZ
M>VM--*>5*YKT:3^83_LLW^R6?(W_`&<2W^RW_P"C3-?Z3?#;^,_P^\'\'_NC
M_;_OW_>7[+^`Z/7_`!C[;3S[).4_WW_6;9/ZN?\`);^H7P?35YZOZ&G5K\M&
MJN.C7F/]V?N3<?WS_P`DWPCK]:>6G^GJTZ/Z5*=:0G2G_0//_I@ZH_T(?\.R
M?Z9_](>R_P#11_=?_1[_`'G_`-(O]X,?_<_^">+_`)>G\>\&C^Q?]?HU>\HM
M\_UYOW+NG[Z_<?[I\!_%U>)31I.JOY5Z@:P_UMOK[7]W?O7ZWQ5T:?`KJKVT
M_.E/.M*9Z^A]3Z_MX/)YO)X8M?W'@\^O0NKS_;?Y-YM7ZO'Z-5]/%O>'G62@
MX=:UO_"@S_AL3^*?%7_AQ3_9J/N/L^X/]$W^RV_W;\'A\O77]\_[XG/\Z]?\
M,^Q\7_-[5^/<V>SG]?-7,?\`4GZ"M(/%^IU5_P!&T>'I_P!OJK_1ZB_W'_JI
M7:?ZS?55I)X?A:*<8]6K7BOPTIFE>AC_`)`/_#?/^@WOS_AO/_9CO[@_Z8<9
M_?\`_P!F/_@'\>_OG_<C#?;?W:_@'[7\#_@7@U^3U^?5;TV]EGNY_7']\[;_
M`%R^C^L^F/A_3ZM&GQ&KJU?BU5K3%*=&/M]_5W]W7?\`5SQ_IO$&KQ=%:Z?+
M1C[:YK\J=&2_G4_[*+_LAV\_]G@_TQ_[+_\`W]ZQ_CG^@G^%?Z0_[P_WKI/[
MJ_8_QG_(?X;_`!?1]W?U>&^GGV1^VO\`6/\`K99_U5\#]\>')I\:OAZ=!U5T
MYK3A\Z5Z,N=_W1^X+C]^>-^[]:ZO#TZJUQ\?;3U_EFG6FG_VS+?^#0__`&'?
MO)K_`)CS_P!(;_JIU!?_`#"G_I)_]4.O?]LRW_@T/_V'?OW_`#'G_I#?]5.O
M?\PI_P"DG_U0Z7_57_0-S_I)V3_=#_AS/^]']X*/^!?Q;_1[_"_XCZ_#]_X_
M7]M]=5N?9ILG_!!_OC;?H?W%]=XH\/7XFG7FE>@MSS_K)_U,YG_?W[Y_<OT;
M^-X/@>+X>*^'Y:_2N/7J[C=J_P`GYOASM,5LG>45&=^;\'7$D<&V9_D;'5E\
M5_>IUA^XIMJS==K6>$HN9DC@-1Y!"PFUGV8;7_P3X]W-Z^F_=9O_`*:V^L^,
M;7IT-X-:UE$VG57P:O2FJJ4Z@+>Q]SL^RVR"[;>A:?6W/T)`B.[ANWQ:`$6Y
MM==-(N"$,FK00^L]$DZCI/Y3]/O3'-V!N#YH9;;S5\6N#.;/ZFV]MR&$S17&
MX:KKO?.Y]Y5-"%MY3CH8IBM]-N/<Q<RO]YI]IF'+UKRK%=Z3F"6XEE)I_H0N
MH8H`WIXA;/Q5%>H)Y2B^Z)'O5L>9+_G26PU+BXM[2*$+7_1FMKF:<I3CX:J:
M5TYIUN0=+_Z)O]%6Q_\`06=J?Z)_[O47]Q3L@4PVU_`K/]O_``X4I*W\NOS:
MSY_/K\O[NOWRWYE_?G[[WK^M/U/]8O%;ZGQM7C>)^+77-:4TT[=.G3VTZ[-<
MG?U6_JQL7]2/I/ZI_3K]+]-I\#PLTT:<4K75^+7JU=U>JC/Y<?\`LC'^S/=[
M?[+0?D!_I3_@6Y?](7^D\8([1.-_TCX_^*?W>_AC"J%1_>;Q>'R7_P`EU7]7
MO);WV_UXO];GD#_7#.T_U<\>'Z;Z37XVOZ8Z/&U5&GPJZM/X_P`NL0_NY?ZQ
M7^NASW_K:?O[^M7@3_5_6^#X&CZN/Q/#\/NU>-HTZOP5KFO1D?YF/^R(_P"C
M'%?[.7X_O===_HX_NH)O],?W=Z?^(_W$^P(J?L;^+[O[W_</JT>?U^/V"O83
M_7B_K+<?ZTA?5V_5^)3Z+10Z/JM?;ZZ-'ZWQ>'C5U)'WF?\`6(_JK;_Z]6C5
MW?2>#_N?JJNOZ;3W:?AU^)^A73XF=/6L=3T/\KH9UI9MS_.U\*9P5H%V+\=(
MJY5UC6),NG8LS/<_D42N/Z$^^@$LOWBS:E5LN3!NOA98S7Y]*5C-N/E0&2G#
M/#KF%'#]U?ZX.^Y<_';?$^#Z;;`:?\U/JSCYB*M/+K:7_EQ?[)+_`*':K_9,
M?L_X3]Y0_P!_?XL*O_2?_'_LV^U_TB?Q0G)&K\/E^V\?^XRWD^T].OWSM]\/
M]=C^MX_UVR_[TT-]-33]-X.K/TNCLT:J:J_J_#XN:==4/NY_ZR7]3&_UE_#^
@AU+]5KK];XM#3ZO7WZOBT:?T/C\'MKU8?[AOK(3K_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
